Jun 2026 (Q2 FY26) — Aug 10, 2026
CeriBell Q2 FY26 — Accelerating Revenue Growth and Delirium Commercialization
Read the full callCeriBell (CBLL) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
CeriBell earnings: last reported Mon, 10 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 28.1 | +32.5% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -71.1 | −0.6 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -19.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$26 +3.83% · +$0.96
Performance +104.6% 1Y
1Y: $12.71 on 17 Oct 2025 → $26. High $27.64 (15 Oct 2026), low $10.92 (4 Nov 2025).
- Previous close
- $25.04
- 52-week range
- $10.92 – $27.64
- One year
- +108.00%
Overview
- Symbol
- CBLL
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
CeriBell earnings calls (CBLL)
Financials
What the filings say
Net profit, year on year: −41% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 19 | 20 | 21 | 23 | 25 | 26 | 28 |
| Operating profit | -10 | -13 | -14 | -15 | -15 | -15 | -21 | -20 |
| Operating margin | −57.8% | −69.5% | −69.3% | −70.5% | −64.8% | −58.9% | −78.3% | −71.1% |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | -10 | -13 | -13 | -14 | -13 | -14 | -20 | -19 |
| Tax rate | — | — | — | 0.0% | — | — | — | 0.0% |
| Net profit | -10 | -13 | -13 | -14 | -13 | -14 | -20 | -19 |
| EPS ($ per share) | -1.85 | — | -0.36 | -0.38 | -0.37 | — | -0.52 | -0.51 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Equity capital | 0 | 0 | 0 |
| Reserves | -126 | -167 | -220 |
| Total liabilities | 24 | 34 | 40 |
| Fixed assets | 2 | 2 | 2 |
| Investments | — | — | 119 |
| Total assets | 59 | 225 | 196 |
| Line item | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Cash from operations | -29 | -35 | -41 |
| Cash from investing | -2 | -2 | -118 |
| Cash from financing | -3 | 197 | 5 |
| Net cash flow | -34 | 160 | -154 |
| Capital expenditure | -1 | -1 | -1 |
| Free cash flow | -30 | -36 | -42 |
Insider filings
192 filings between Nov 11, 2025 and Oct 1, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$22.93M
100 sales by 10 insiders
85% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 13
- Award — granted as compensation
- 74
- Option exercise — converted options into shares
- 5
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Chao Xingjuan | — | $11.13M | Sep 15, 2026 |
| TPG GP A, LLC | — | $4.07M | Jun 26, 2026 |
| Parvizi Josef | — | $2.12M | Feb 19, 2026 |
| Blumberg Scott | — | $1.73M | Sep 15, 2026 |
| Woo Raymond | — | $1.71M | Oct 1, 2026 |
| BURKE WILLIAM W | — | $764.5K | Jun 30, 2026 |
| Foehr David | — | $736.2K | Sep 8, 2026 |
| Taylor Joseph Michael | — | $407.7K | Aug 13, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Woo Raymond Chief Technology Officer | Option exercise 10b5-1 plan | 23 | $108 |
| Oct 1, 2026 | Woo Raymond Chief Technology Officer | Sale 10b5-1 plan | 4,887 | $119.1K |
| Oct 1, 2026 | Woo Raymond Chief Technology Officer | Option exercise 10b5-1 plan | 4,864 | $17.8K |
| Sep 15, 2026 | Blumberg Scott Chief Financial Officer | Sale 10b5-1 plan | 846 | $21.1K |
| Sep 15, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 846 | $8.0K |
| Sep 15, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 20,846 | $521.8K |
| Sep 8, 2026 | Woo Raymond Chief Technology Officer | Sale 10b5-1 plan | 4,887 | $118.9K |
| Sep 8, 2026 | Foehr David Senior VP, Finance and PAO | Sale 10b5-1 plan | 1,755 | $42.6K |
| Sep 8, 2026 | Foehr David Senior VP, Finance and PAO | Sale 10b5-1 plan | 7,500 | $181.9K |
| Sep 8, 2026 | Woo Raymond Chief Technology Officer | Option exercise 10b5-1 plan | 23 | $108 |
| Sep 8, 2026 | Woo Raymond Chief Technology Officer | Option exercise 10b5-1 plan | 4,864 | $17.8K |
| Sep 8, 2026 | Woo Raymond Chief Technology Officer | Option exercise 10b5-1 plan | 8,389 | $18.8K |
| Sep 8, 2026 | Foehr David Senior VP, Finance and PAO | Option exercise 10b5-1 plan | 7,500 | $35.3K |
| Sep 2, 2026 | Blumberg Scott Chief Financial Officer | Sale 10b5-1 plan | 652 | $16.3K |
| Sep 2, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 23,554 | $110.7K |
| Sep 2, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 39,540 | $973.1K |
| Sep 2, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 1,446 | $6.8K |
| Sep 2, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 652 | $6.1K |
| Aug 24, 2026 | Foehr David Senior VP, Finance and PAO | Sale 10b5-1 plan | 859 | $20.6K |
| Aug 21, 2026 | Woo Raymond Chief Technology Officer | Sale | 1,979 | $47.5K |
| Aug 21, 2026 | Chao Xingjuan President and CEO | Sale | 6,068 | $145.8K |
| Aug 21, 2026 | Manni Joseph S. Chief Revenue Officer | Sale | 1,361 | $32.7K |
| Aug 21, 2026 | Blumberg Scott Chief Financial Officer | Sale | 1,521 | $36.5K |
| Aug 21, 2026 | Foehr David Senior VP, Finance and PAO | Sale 10b5-1 plan | 993 | $23.9K |
| Aug 19, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 6,179 | $29.0K |
| Aug 19, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 31,415 | $786.3K |
| Aug 19, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 27,333 | $257.2K |
| Aug 19, 2026 | Blumberg Scott Chief Financial Officer | Sale 10b5-1 plan | 33,512 | $838.8K |
| Aug 18, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 300 | $2.8K |
| Aug 18, 2026 | Blumberg Scott Chief Financial Officer | Sale 10b5-1 plan | 990 | $24.8K |
| Aug 18, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 2,199 | $55.0K |
| Aug 18, 2026 | Blumberg Scott Chief Financial Officer | Option exercise 10b5-1 plan | 690 | $3.2K |
| Aug 13, 2026 | Chao Xingjuan President and CEO | Option exercise | 25,000 | $91.3K |
| Aug 13, 2026 | Chao Xingjuan President and CEO | Option exercise | 8,096 | $18.1K |
| Aug 13, 2026 | Taylor Joseph Michael Director | Sale | 13,095 | $306.4K |
| Aug 3, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 23,554 | $110.7K |
| Aug 3, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 1,446 | $6.8K |
| Aug 3, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 39,000 | $714.5K |
| Jul 28, 2026 | West Thomas A. Director | Award | 16,011 | $0 |
| Jul 28, 2026 | O'KEEFE SHARON Director | Award | 16,011 | $0 |
| Jul 7, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 1,446 | $6.8K |
| Jul 7, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 14,000 | $278.6K |
| Jul 7, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 23,554 | $468.7K |
| Jul 7, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 23,554 | $110.7K |
| Jul 7, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 1,446 | $28.8K |
| Jun 30, 2026 | BURKE WILLIAM W Director | Sale 10b5-1 plan | 2,207 | $43.8K |
| Jun 26, 2026 | TPG GP A, LLC Insider | Sale | 202,368 | $4.07M |
| Jun 11, 2026 | Taylor Joseph Michael Director | Sale | 5,500 | $101.3K |
| Jun 8, 2026 | Chao Xingjuan President and CEO | Option exercise 10b5-1 plan | 1,446 | $6.8K |
| Jun 8, 2026 | Chao Xingjuan President and CEO | Sale 10b5-1 plan | 14,000 | $256.6K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Ceribell, Inc.
Free account. Everything above stays public.
Write why you follow Ceribell, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading